Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23080162 | 0.86 | ACHE (0.34) | ACHEALDH1A1LMNACHRNB2CHRNB4 | |
| SCHEMBL21465896 | 0.84 | — | — | |
| SCHEMBL22570807 | 0.83 | ACHE (0.47) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22343075 | 0.82 | ACHE (0.38) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20980231 | 0.81 | ADRB2 (0.32) | — | |
| SCHEMBL26759938 | 0.81 | GLP1R (0.38) | — | |
| SCHEMBL20113001 | 0.80 | ACHE (0.41) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20980230 | 0.80 | ALB (0.38) | — | |
| SCHEMBL22570776 | 0.80 | ACHE (0.39) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22570793 | 0.80 | ACHE (0.37) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077195-B2 | IL-2 conjugates and methods of use thereof | Synthorx, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210070827-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200330601-A1 | IL-2 Conjugates and Methods of Use Thereof | Synthorx, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200246467-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | SYNTHORX INC (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | IL15, IL15RA, IL5 | ACHE 4404/4885ALDH1A1 329/4885LMNA 4040/4885 |
| US-11077195-B2 | IL-2 conjugates and methods of use thereof | IL2, IL2RA, IL15 | ACHE 4230/4885ALDH1A1 476/4885LMNA 3491/4885 |
| US-20210070827-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | ACHE 4348/4885ALDH1A1 608/4885LMNA 3358/4885 |
| US-20200246467-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, IL15 | ACHE 4230/4885ALDH1A1 476/4885LMNA 3491/4885 |
| US-20200330601-A1 | IL-2 Conjugates and Methods of Use Thereof | IL2, IL2RA, IL15 | ACHE 4230/4885ALDH1A1 476/4885LMNA 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.